With the temporary ‘ETAP’ solution, France has provided a pathway to establish national reimbursement for digital solutions in specific indications. In addition, it has been possible to apply for ‘brand-specific’ reimbursement with the possibility to establish a higher tariff based on the clinical value.
The French government is currently in process to implement a revised program that will follow the traditional ‘generic’ and ‘brand specific’ reimbursement.
In this webinar, Michel Verhasselt, who has actively been leading the efforts for the only 2 brand specific reimbursement registrations, will give an overview of the historical experience and what the anticipated changes are.
Speaker
Michel Verhasselt CEO and founder of Meditech Access, which he founded 2012. He holds a master's degree in business administration and health economics from the Catholic University of Lille. He has 25 years’ experience in the field of health economics, HTA, DRG coding and reimbursement, especially for the medical device industry, make him an expert. He conducts public affairs and market access activities for France, Belgium and Switzerland.
Registration below